Esra Bilir: Predictive value of homologous recombination deficiency in primary tubo-ovarian high-grade serous carcinoma

Esra Bilir shared a post on LinkedIn: 

“Thrilled to share the publication of our protocol, ‘Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma,’ now available Cochrane.

Our shared passion for combating Ovarian Cancer united us. Publishing with Cochrane has been a dream since my medical school days, and I am incredibly grateful to our amazing team at ENYGO-European Society of Gynaecological Oncology for bringing together such brilliant minds.

A special thanks to Cochrane USA, Paola Andrenacci and Tiffany Gust Duque for the continuous opportunities by shaping a brighter, more inclusive future for all Equality Mentoring Program—proud to be a Y2 Mentee.

Shout out to our dream team: Tibor Zwimpfer, Hannah Ewald, Madawa Jayawardana, Christian Appenzeller-Herzog, Nicolò Bizzarri, Zoia Razumova, Joanna Kacperczyk-Bartnik, Professor Viola Heinzelmann-Schwarz, Michael Friedlander, David Bowtell, and Dale Garsed.”

Read further.
Source: Esranur Aydın/LinkedIn

Esra Bilir is a Social Media Committee Member for the International Urogynecological Association (IUGA) and a resident in the Department of Obstetrics and Gynecology at Universitätsklinikum Schleswig-Holstein.

She also serves as Co-Chair of the ENYGO-ESGO Task Force on Embracing Gender Equality in Gynecological Oncology and is a mentee with Cochrane. Additionally, she works as a Research Associate with the Pan-Arabian Research Society of Gynecological Oncology (PARSGO).